4.4 Article

Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients

期刊

ALLERGOLOGY INTERNATIONAL
卷 66, 期 2, 页码 326-331

出版社

JAPANESE SOCIETY ALLERGOLOGY
DOI: 10.1016/j.alit.2016.08.008

关键词

Allergic rhinitis; Disease severity; Eosinophils; Soluble programmed cell death-1 ligand-1; Symptom intensity

资金

  1. Kurdistan University of Medical Sciences [198]

向作者/读者索取更多资源

Background: T-cell response outcome is determined by co-stimulatory/inhibitory signals. Programmed cell death-1 ligand-1 (PD-L1) is a member of these co-signaling molecules with known soluble form in human serum. Soluble PD-Ll (sPD-L1) is also recognized in patients with some types of malignancy or autoimmune disorders, though there are few studies on sPD-L1 roles in allergic diseases. The purpose of this survey was to evaluate the association between sPD-L1 levels with eosinophil count as well as disease severity in allergic rhinitis (AR) patients. Methods: 90 patients with AR were selected. Disease severity was determined by a modified Allergic Rhinitis and its Impact on Asthma (ARIA) classification as mild, moderate and severe. Whole blood samples were collected. Then eosinophil count and serum sPD-L1 were detected by a hematologic analyzer and a commercial ELISA kit. Results: 13 (14.44%), 31 (34.44%), and 46 (51.12%) of patients had mild, moderate and severe disease, respectively. The mean levels of sPD-L1 and eosinophil count were ascertained 1838 14.42 ng/ml and 422.43 262.26 cell/ 1. A significant inverse correlation was determined between sPD-L1 levels and eosinophil count (r = 0.364, P < 0.001). Moreover, we detected a significant negative association between sPD-L1 levels and disease severity (r = 0.384, P < 0.001). Conclusions: It is deduced that sPD-L1 can be used as a helpful marker to determine the severity of AR. Furthermore, this study indicated that sPD-L1 may have an inhibitory role in AR development, and its modulation may be considered as a useful accessory therapeutic approach for reduction of AR progression. Copyright (C) 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据